The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CD3+ tumor-infiltrating lymphocytes (TILs) as prognostic in patients (pts) with stage II colon cancer (CC) not treated with adjuvant chemotherapy (ADJ).
 
Edoardo Francini
Honoraria - Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag
Research Funding - Roche; Roche; Roche; Roche
Travel, Accommodations, Expenses - Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag
 
Fang-Shu Ou
No Relationships to Disclose
 
Stefano Lazzi
No Relationships to Disclose
 
Roberto Petrioli
No Relationships to Disclose
 
Andrea Giovanni Multari
No Relationships to Disclose
 
Guido Pesola
No Relationships to Disclose
 
Luciana Messuti
No Relationships to Disclose
 
Elena Colombo
No Relationships to Disclose
 
Virginia Livellara
No Relationships to Disclose
 
Serena Bazzurri
No Relationships to Disclose
 
Sara Cherri
No Relationships to Disclose
 
Miano Salvatora
No Relationships to Disclose
 
Eric Wolfe
No Relationships to Disclose
 
Steven R Alberts
No Relationships to Disclose
 
Joleen Marie Hubbard
Consulting or Advisory Role - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst)
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); eFFECTOR Therapeutics (Inst); eFFECTOR Therapeutics (Inst); eFFECTOR Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Senhwa Biosciences (Inst); Senhwa Biosciences (Inst); Senhwa Biosciences (Inst); Senhwa Biosciences (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Treos Bio (Inst); Treos Bio (Inst); Treos Bio (Inst); Treos Bio (Inst)
 
Harry H. Yoon
Honoraria - Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; BeiGene; BeiGene; BeiGene; BeiGene; LSK Biopharma; LSK Biopharma; LSK Biopharma; LSK Biopharma; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; BeiGene; BeiGene; BeiGene; BeiGene; LSK Biopharma; LSK Biopharma; LSK Biopharma; LSK Biopharma; Macrogenics; Macrogenics; Macrogenics; Macrogenics; Merck; Merck; Merck; Merck
Research Funding - Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Lilly/ImClone (Inst); Lilly/ImClone (Inst); Lilly/ImClone (Inst); Lilly/ImClone (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Lilly; Lilly; Lilly; Lilly
 
Guido Francini
No Relationships to Disclose